Ila Saunders, PharmD, BCOP Research Interests Impact of clinical pharmacy services in a matrix cancer center Impact of a “Transitions of Care” clinical.

Slides:

Advertisements

Similar presentations

Pediatric Cancer & Leukemia December 4, Pediatric Oncology  Acute leukemia  Brain tumors  Lymphoma  Neuroblastoma  Wilm’s tumor  Rhabdomyosarcoma.

Advertisements

Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor,

Transplantation of hematopoietic stem cells in pediatric oncology Vladivostok State Medical University Foreign languages department Vladivostok 2012 Scientific.

Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest and Hazel Craige Distinguished Professor of Cardiovascular.

UCDAVIS Health System Pharmacy Residencies Dispensing Quality & Excellence Pharmacy Practice Residency All ASHP Accredited Required experiences: Management,

Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Doug Brutlag Professor Emeritus of.

Jan D. Hirsch, BS Pharm, PhD Research Interests Pharmacoeconomics & Outcomes Research “Value” of Pharmacist Services & Pharmaceuticals - Economic, clinical.

Leukemia By: Kalpana Ganeshan.

Grace M. Kuo, PharmD, MPH, PhD Research Interests: Health Services Research (Medication Safety; Pharmacist Practice; Education) DomainTopic AreasProjects.

Bradley Moore Natural Products, Genomics, Drug Discovery Currently funded projects: 1. Bioengineering marine antibiotics (NIAID – R01) 2. Biosynthesis.

Why PLANET-2 needs to succeed? Simon Stanworth Anna Curley.

Copyright © 2008 Delmar Learning. All rights reserved. Unit 36 Subacute Care.

Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2.

Bill Gerwick Research Interests Characterizing the ‘weird and wonderful’ natural products of marine algae and cyanobacteria Drug discovery from marine.

Jonathan H. Watanabe, PharmD, MS, PhD Research Interests Analysis of health services use and costs for patients without access to medications (applying.

5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].

Transplant Creations1 Treatment & Transplant Program to improve disease outcome Transplant Creations Marlies Van Hoef.

DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.

Sandy Jones Public Health Advisor Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion April.

Surviving Childhood Cancer: What’s Next? Trisha Kinnard PAS 646.

Cancer of the blood: Leukemia

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

David Adler Research Interests Pharmaceutics Solubility - Phenytoin in IV Solutions Bioavailability/Clinical Equivalence - Sodium Warfarin - RCT Clinical.

Leukemia Shannon Esmas Amanda Walzer English 100 ESP 2 November, 2015.

Charles E. Daniels, BS Pharm., Ph.D. Research Interests Medication use and outcomes quality Medication distribution technology application Multihospital.

Shirley M. Tsunoda Liver Transplant, Drug Metabolism/PK Research Interests Investigating the genetic and environmental factors that influence variability.

Rabia Atayee Research Interests Opioid therapy Neuropathic pain and adjuvant therapy for pain Role of palliative care in the healthcare setting Teaching.

Åsa Gustafsson Research Interests Cardiovascular Disease Pathways that regulate life and death of cardiac myocytes Regulation of mitochondrial dynamics.

TREATMENT. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.

Chronic Disease Tracking System  Problem  The current healthcare model focuses on one patient at a time in the office.  Chronic disease leads to higher.

Treatment. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.

미 국 에 서 의 병 원 약 사 의 역 할 서 옥 경, Pharm.D. 서울대학교 약학대학.

CANCER THERAPY  Surgery  Radiation Therapy  Chemotherapy  Stem Cell Transplant  Immunotherapy  Targeted Therapy  Hormone Therapy  Precision Medicine.

Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.

HAPLOIDENTICAL STEM CELL TRANSPLANT

Hematopoietic Stem Cell Transplantation (HSCT)

ASCO’s Quality Training Program Project Title: Improving oral chemotherapy fulfillment processes and implementation of a pharmacist- managed oral chemotherapy.

P Ferguson, R Hills, A Grech, L Kjeldsen, M Dennis, P Vyas, R Clark, N Russell, C Craddock, On behalf of the NCRI AML Working Group. An operational definition.

Pharmacoepidemiology Of Multiple Myeloma Treatment Patterns, Safety And Effectiveness In Real Life Conditions Aurore Palmaro Thesis directors: Dr Maryse.

Bone Marrow Transplant

of Patients with Acute Myocardial Infarction (AMI)

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

Maury S et al. Proc ASH 2015;Abstract 1.

Lenograstim Chemical Formula : C840-H1330-N222-O242-S8

Challenges of realising the EET strategy

Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.

Figure 3 Care needs of patients with advanced-stage cancer

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.

Timing for HCT Consultation

Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

Mitchell S. Cairo, Willi Woessmann, John Pagel

Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe Shahram.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

What is quality in a transplant program?

The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation Karim E. Abou-Nassar, Haesook.

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Bridge to transplant following Bv+Bs regimen.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Timing for HCT Consultation

Close Monitoring of Cyclosporine A Concentration as a Means of Preventing Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Recipients Marietta.

Mary Eapen Biology of Blood and Marrow Transplantation

Hematopoietic stem cell transplantation in HCV-infected patients

by Lapo Alinari, and Kristie A. Blum

Presentation transcript:

Ila Saunders, PharmD, BCOP Research Interests Impact of clinical pharmacy services in a matrix cancer center Impact of a “Transitions of Care” clinical pharmacy program in an allogeneic stem cell transplant (SCT) population Adherence to oral chemotherapy in the thoracic oncology population—how does it affect outcome? Use of temsirolimus in the treatment of chronic graft-versus- host-disease

Core Expertise Blood & marrow transplantation Immunosuppression and therapeutic drug monitoring Post-allogeneic and autologous SCT medication management Management of infectious complications s/p allogeneic SCT Management of acute and chronic graft-versus-host disease Vaccinations/survivorship Thoracic oncology Chemotherapy teaching/education Adherence evaluation/monitoring Medication reconciliation

Proposed Collaborations with SSPPS Faculty Development of strategic plan for clinical pharmacy at Moores Cancer Center (with Chuck Daniels) Address clinical pharmacy service growth and impact